Luciano Mazzoccoli

Dr. Luciano Mazzoccoli


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Experimental and Molecular Pathology
Verified
Journal Article
Closed access
MRMarcela Cristina Robaina
Marcela Cristina Robaina
LMLuciano Mazzoccoli
Luciano Mazzoccoli
VAViviane Oliveira Arruda
Viviane Oliveira Arruda
FRFlaviana Ruade de Souza Reis
Flaviana Ruade de Souza Reis
AAAlexandre Gustavo Apa
Alexandre Gustavo Apa
CKClaudete Klumb
Claudete Klumb

13 June 2024 in Cancers
Verified
Journal Article
Open access
PDF file
LMLuciano Mazzoccoli
Luciano Mazzoccoli
Bei LiuBei Liu
Bei Liu
Among professional antigen-presenting cells, dendritic cells (DCs) orchestrate innate and adaptive immunity and play a pivotal role in anti-tumor immunity. DCs are a heterogeneous population with varying functions in the tumor microenvironment (TME). Tumor-associated DCs differentiate developmentally and functionally into three main subsets: conventional DCs (cDCs), plasmacytoid DCs (pDCs), and monocyte-derived DCs (MoDCs). There are two major subsets of cDCs in TME, cDC1 and cDC2. cDC1 is critical for cross-presenting tumor antigens to activate cytotoxic CD8+ T cells and is also required for priming earlier CD4+ T cells in certain solid tumors. cDC2 is vital for priming anti-tumor CD4+ T cells in multiple tumor models. pDC is a unique subset of DCs and produces type I IFN through TLR7 and TLR9. Studies have shown that pDCs are related to immunosuppression in the TME through the secretion of immunosuppressive cytokines and by promoting regulatory T cells. MoDCs differentiate separately from monocytes in response to inflammatory cues and infection. Also, MoDCs can cross-prime CD8+ T cells. In this review, we summarize the subsets and functions of DCs. We also discuss the role of different DC subsets in shaping T cell immunity in TME and targeting DCs for potential immunotherapeutic benefits against cancer.

5 April 2016 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
MRMarcela Cristina Robaina
Marcela Cristina Robaina
RFRoberta Soares Faccion
Roberta Soares Faccion
LMLuciano Mazzoccoli
Luciano Mazzoccoli
LRLidia Maria M. Rezende
Lidia Maria M. Rezende
EQEduardo Queiroga
Eduardo Queiroga
CKClaudete Klumb
Claudete Klumb

9 January 2018 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
LMLuciano Mazzoccoli
Luciano Mazzoccoli
MRMarcela Cristina Robaina
Marcela Cristina Robaina
AAAlexandre Gustavo Apa
Alexandre Gustavo Apa
MBMartin Bonamino
Martin Bonamino
LPLuciana Wernersbach Pinto
Luciana Wernersbach Pinto
CKClaudete Klumb
Claudete Klumb

1 February 2012 in International Immunopharmacology
Verified
Journal Article
Closed access
SCSandra Castro
Sandra Castro
celso de oliveira Rezende Júniorcelso de oliveira Rezende Júnior
celso de oliveira Rezende Júnior
Caio Cesar Souza AlvesCaio Cesar Souza Alves
Caio Cesar Souza Alves
ADAlyria T. Dias
Alyria T. Dias
LALívia L. Alves
Lívia L. Alves
AFAna Paula Ferreira
Ana Paula Ferreira

1 November 2009 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
PDF file
CACaroline de Souza Almeida
Caroline de Souza Almeida
CAClarice Abramo
Clarice Abramo
Caio Cesar Souza AlvesCaio Cesar Souza Alves
Caio Cesar Souza Alves
LMLuciano Mazzoccoli
Luciano Mazzoccoli
AFAna Paula Ferreira
Ana Paula Ferreira
HTHenrique Couto Teixeira
Henrique Couto Teixeira
Chemokines recruit and activate leukocytes, assisting granuloma formation. Herein, we evaluated plasma chemokines in patients with active tuberculosis (ATB) and after completing treatment (TTB) and compared them to BCG-vaccinated healthy controls (HC). Levels of chemokines were measured by cytometric bead array. Levels of CXCL8, CXCL9 and CXCL10 were higher in ATB patients compared to HC, but they decreased in TTB. Levels of CCL2 and CCL5 in ATB patients were similar to those observed in HC. Thus, the high levels of CXC-chemokines detected during ATB, which can modulate the trafficking of immune cells from the periphery to the site of infection, were reversed by anti-mycobacterial treatment